PARLIAMENTARY WRITTEN QUESTION
(17 April 2025)

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of US tariffs on the domestic supply of (a) methylphenidate and (b) pancreatic enzyme replacement therapy.

Asked by:
Jess Brown-Fuller (Liberal Democrat)

The Department is working closely with life sciences stakeholders and other Government departments to assess the potential impact of United States tariffs on global medicine supply chains. We have a range of well-established processes to mitigate risks to patients where there are shortages. We will continue to review the need to utilise these procedures as more information becomes available on the impact of tariffs on any specific products or companies.

Answered by:
()